Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2020 | COVID-19 in the GAIA/CLL13 trial

Barbara Eichhorst • 25 Sep 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax
GAIA/CLL13

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses how COVID-19 has impacted the GAIA/CLL13 trial (NCT02950051). Between March and April 2020, 7 patients in the clinical trial tested positive for COVID-19. Of the 7 patients, 2 died. However, in the recent resurgence of COVID-19, no patients involved in the trial have tested positive for the virus. This is the first analysis of chronic lymphocytic leukemia (CLL) patients receiving venetoclax combination therapy as a first-line treatment. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals